Summary & Overview
HCPCS C9042: Bendamustine (Belrapzo) Injection, 1 mg
HCPCS Level II code C9042 denotes the unit-dose billing for bendamustine hydrochloride (Belrapzo), recorded per 1 mg of the injectable antineoplastic. This code is used when documenting and billing for the drug supply component of bendamustine administration in oncology care. Nationally, accurate coding of high-cost chemotherapeutic agents like bendamustine matters for facility reimbursement, inventory control, and treatment cost transparency.
Key payers considered in this coverage include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical and billing context, typical sites of service, and the payer landscape. The publication provides benchmark-oriented information about how C9042 is applied across major national payers, highlights common billing considerations for injectable oncology agents, and summarizes policy or coverage factors that affect reimbursement for high-cost drugs.
The report is intended for health system financial officers, oncology billing staff, and policy analysts seeking a clear, national-level briefing on coding and payer interaction for bendamustine (Belrapzo). It outlines what to expect when using C9042, clarifies where the service is typically delivered, and signals where readers can look for payer-specific coverage rules and reimbursement benchmarks.
Billing Code Overview
HCPCS Level II code C9042 describes Injection, bendamustine hcl (belrapzo), 1 mg. This code represents the billed supply or drug administration unit for bendamustine hydrochloride marketed as Belrapzo when dispensed or administered in a clinical setting. The service type is injectable chemotherapy/antineoplastic agent and the typical site of service is outpatient infusion center or hospital outpatient department, where oncology infusions and parenteral chemotherapeutic agents are commonly administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old female with relapsed follicular lymphoma presents to an outpatient oncology infusion center for administration of bendamustine hydrochloride (Belrapzo) as part of second-line chemotherapy. The oncology nurse verifies current weight and renal/hepatic function, confirms premedication status, obtains baseline vital signs and venous access, and reviews the most recent labs including complete blood count and metabolic panel. The medication is reconstituted and dosed per weight (billing code C9042 denotes injection, bendamustine HCl, 1 mg unit billing). The infusion is administered via peripheral or central intravenous access over the recommended infusion time with monitoring for infusion reactions. After infusion, the patient remains for an observation period for adverse events and receives supportive care orders such as antiemetic prophylaxis and growth factor planning as indicated. Documentation includes indication, dose in mg, lot and National Drug Code if required, infusion start/stop times, pre- and post-vital signs, patient tolerance, and any adverse events. Typical payors for authorization and claims adjudication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service | When another service/procedure is performed on a separate anatomical site or during a separate encounter and should be reported as distinct from an infusion-related service |